TNF Pharmaceuticals and Renova Health Harness AI for Faster Drug Development

TNF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for autoimmune and inflammatory disorders, has partnered with Renova Health to employ advanced AI and machine learning technologies. This collaboration aims to pinpoint high-risk patient categories that could significantly benefit from interventions designed to preserve lean muscle mass during GLP-1 therapy, commonly used for diabetes, weight loss, and managing chronic weight issues. Aligning with recent FDA guidance on AI, the partnership analyzes data from 30,000 patients to identify these high-risk groups, facilitating the recruitment of suitable candidates to expedite the development of the isomyosamine drug.

Dr. Mitchell Glass, President and Chief Medical Officer of TNF Pharmaceuticals, emphasized the importance of Renova Health’s AI platform in the collaboration. "The technology has allowed us to examine a wide range of underlying conditions, symptoms, acute events, and concurrent medications across thousands of patients. This enables us to identify precise patient subsets for whom isomyosamine treatment could be especially advantageous," Dr. Glass stated.

Renova Health's proprietary AI and machine learning capabilities, including cutting-edge natural language processing (NLP) and large language model (LLM) platforms, provide crucial advantages to TNF Pharmaceuticals. These tools enable swift review and analysis of extensive patient records to identify those who might best benefit from isomyosamine. This target group includes patients with chronic conditions like diabetes, COPD, chronic kidney disease, or sarcopenia/frailty, those who have experienced acute inflammation-related medical events, such as falls or bone fractures, and individuals taking GLP-1 medications.

David Jacobs, CEO of Renova Health, highlighted the transformative potential of their technology. "We're excited to collaborate with TNF Pharmaceuticals to advance precision medicine through our state-of-the-art NLP, LLM, and AI platform. Our technology goes beyond traditional big data analytics by creating highly detailed patient profiles and identifying optimal cohorts for isomyosamine based on underlying conditions, acute events, and medication profiles," Jacobs noted. "Additionally, our platform reveals the nuanced impact of individual physician practices, such as different diagnostic codes for GLP-1 prescriptions, which can significantly affect cohort selection and study outcomes. This exceptional precision allows TNF Pharmaceuticals to target patients who stand to gain the most, thereby speeding up study timelines and enhancing therapeutic impact."

Renova Health works with large clinical practices, hospital systems, and accountable care organizations to improve patient outcomes while reducing costs. The company's success stems from its committed Personal Health Advocates, who build personal, trust-based relationships with patients, leading to deeper insights and improved healthcare outcomes.

Isomyosamine, a newly developed plant alkaloid small molecule, plays a role in regulating the immune system by modulating pro-inflammatory cytokines, including TNF-alpha (TNF-α). TNF-α is a crucial player in the inflammatory process and aging, and its regulation is pivotal in addressing various age-related diseases. TNF Pharmaceuticals is developing isomyosamine to treat diseases characterized by acute or chronic inflammation.

Alongside isomyosamine, TNF Pharmaceuticals is also developing Supera-CBD, a novel synthetic cannabidiol (CBD) derivative aimed at treating chronic pain, addiction, and epilepsy. Supera-CBD is intended to advance the rapidly expanding CBD market, which includes both FDA-approved drugs and unregulated CBD products.

By leveraging AI and machine learning technologies, TNF Pharmaceuticals and Renova Health are paving the way for more precise and efficient recruitment of patients for clinical studies, potentially revolutionizing the development of treatments for chronic inflammatory diseases.